重度嗜酸粒细胞性哮喘美泊利单抗治疗反应轨迹与临床缓解
基于澳大利亚美泊利单抗登记研究,在3、6、12个月评估重度嗜酸粒细胞性哮喘患者的治疗反应,用基于组的轨迹模型识别出三条反应轨迹,12个月临床缓解率分别为36.5%、25.9%和5.7%(p<0.001),并发现各轨迹的基线预测因素不同。
要点
- 美泊利单抗治疗反应可分三条轨迹,临床缓解率差异显著
- 「反应良好且OCS用量少」组12个月缓解率36.5%
- 「阻塞且反应较差」组缓解率仅5.7%,需早期识别
核心结论
- 重度嗜酸粒细胞性哮喘对美泊利单抗的治疗反应呈三条轨迹,各轨迹达到临床缓解的比例不同,反应异质性可能影响缓解的实现。
研究设计与样本
- 使用澳大利亚美泊利单抗登记研究数据,在3、6、12个月评估治疗反应。
- 采用基于组的轨迹模型识别治疗反应轨迹。
- 比较各轨迹12个月临床缓解比例,并用logistic回归分析基线预测因素。
主要发现
- 识别出三组:第1组「反应良好且OCS用量少」(n=170)、第2组「反应良好的晚发型哮喘」(n=58)、第3组「阻塞且反应较差」(n=70)。
- 12个月临床缓解率:第1组36.5%、第2组25.9%、第3组5.7%(p<0.001)。
- 以第3组为参照,第1组基线OCS剂量较低。
- 以第3组为参照,第2组基线FEV1占预计值百分比更高、AQLQ评分更高、OCS剂量更高并伴鼻息肉。
关键数值与推荐
- 临床缓解定义为症状控制良好、无急性加重且未使用口服糖皮质激素(OCS)管理哮喘。
- 12个月临床缓解率:第1组36.5%,第2组25.9%,第3组5.7%(p<0.001)。
临床怎么用
- 可依据基线特征预判美泊利单抗治疗反应轨迹,对「阻塞且反应较差」轨迹患者加强随访与方案评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit from mepolizumab, which improves symptoms and reduces exacerbations, potentially leading to clinical remission in a subgroup. This study aimed to identify treatment response trajectories to mepolizumab for severe eosinophilic asthma and to assess the achievement of clinical remission. METHODS: Data from the Australian Mepolizumab Registry were used to assess treatment responses at 3, 6 and 12 months. The treatment response trajectories were identified using a group-based trajectory model. The proportions achieving clinical remission at 12 months, which was defined as well-controlled symptoms, no exacerbations and no oral corticosteroid (OCS) use for asthma management, were compared between trajectories, and baseline predictors of the trajectories were identified using logistic regression analysis. RESULTS: We identified three trajectory groups: Group 1, "Responsive asthma with less OCS use" (n=170); Group 2, "Responsive late-onset asthma" (n=58); and Group 3, "Obstructed and less responsive asthma" (n=70). Groups 1 and 2 demonstrated higher proportions achieving clinical remission at 36.5% and 25.9%, respectively, compared to Group 3 with 5.7% (p<0.001). Baseline predictors for assigned groups included lower OCS dose in Group 1; greater forced expiratory volume in 1 s percentage predicted, higher Asthma Quality of Life Questionnaire score, higher OCS dose and nasal polyps in Group 2; with Group 3 as the reference. CONCLUSIONS: Treatment response to mepolizumab in severe eosinophilic asthma follows three trajectories with varying proportions achieving clinical remission and differing baseline characteristics. Treatment response variability may influence the achievement of clinical remission with mepolizumab therapy.
引用
- Hamada Y, Thomas D, Harvey ES, et al. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2025. PMID: 39401859. doi:10.1183/13993003.00782-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。